Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common ED drug boost fertility in PCOS?

NCT ID NCT07769476

Disease control Sponsor: Nishtar Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial asks whether adding sildenafil citrate to the standard fertility drug clomiphene citrate can improve ovulation and pregnancy rates in women with polycystic ovary syndrome (PCOS) who have been trying to conceive for over two years. About 98 women aged 18–45 will be randomly assigned to receive either clomiphene alone or clomiphene plus sildenafil for 12 weeks. Researchers will track ovulation, pregnancy, and uterine lining thickness to see if the combination offers an advantage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clomiphene citrate plus sildenafil citrate
What this could lead to
If adding sildenafil works, it could offer a simple, affordable way to boost ovulation and pregnancy chances for women with PCOS who struggle to conceive.
What could go wrong
This is a small, early-stage comparison, and the added benefit of sildenafil is uncertain. Side effects or lack of effect are possible, and results may not apply to all women with PCOS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

98 people

The number who actually took part.

Started

Jul 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with PCOS, * Sub-fertility attributed to PCOS, \> 2 years Exclusion Criteria: * Comorbidities; diabetes, hypertension * Chronic medical illness (liver, heart, kidney disease) * Undergone ovarian drilling * Recent administration of hormonal therapy * Abnormal prolactin levels (\>500 mIU/L), or thyroid function tests (TSH \>5.2 mIU/L, T3 \<70 ng/dl and T4 \<5.2 μg/dl) * Obstructed fallopian tubes documented on hysterosalpingography and * Abnormal semen analysis of their partners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycystic ovarian syndrome (PCOS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycystic ovarian syndrome (PCOS) Polyendocrine metabolic ovarian syndrome (PMOS)

Contacts and locations

Locations

  • Nishtar Medical University

    Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.